What's truly remarkable about this latest double-digit move lower is that Adaptimmune has had nothing but success in the clinic this year. In fact, the biotech is expected to file its first regulatory ...

Struggling cancer cell therapy developer Adaptimmune is backing out of commercial drug manufacturing, announcing Monday it will sell its approved medicine Tecelra and two late-stage assets to US ...

4 analysts have shared their evaluations of Adaptimmune Therapeutics (NASDAQ:ADAP) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table ...

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $6.17 million, and the earnings are expected to come in ...

At the beginning of August, preparations for Adaptimmune’s allogeneic MAGE-A4 program seemed to be near the finish line, with the company’s UK manufacturing facility almost done. The plan at the time ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. What Adaptimmune Does and Why Its Focus Is Changing ...

Adaptimmune's approach to fighting cancer involves taking T cell receptors from patients, modifying them, and then reinfusing those back into the patient. The engineered T cells increase the immune ...

The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...

Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the ...

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced ...

Biopharmaceutical company Adaptimmune rocketed as much as 338% in Monday trading after announcing "partial responses" (PRs) for four tumor indicators. The company's SPEAR T-cell platform delivered two ...